Compare iShares 10 20 Year Treasury Bond ETF (TLH) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 10 20 Year Treasury Bond ETF vs Twist Bioscience Corp — how do they compare? iShares 10 20 Year Treasury Bond ETF trades at $97.83, while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| TLH | TWST | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $105.36 | $102.88 |
52-Week Low | $97.13 | $24.16 |
Market Cap | — | $5.45B |
Enterprise Value | — | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLH trades at $98.13, down 0.56% over 24 hours, with technical indicators signaling a bearish trend. The stock faces resistance near $99 and support at $97. Recent dividend payments of $0.41 and $0.36 in mid-2026 provide income, but key financial ratios like P/E and ROE are unavailable, limiting fundamental clarity. Broader market volatility, driven by Federal Reserve uncertainty and geopolitical tensions, adds to the cautious backdrop.
The outlook for TLH remains guarded due to weak technical momentum and lack of visible fundamental strength. Investment opportunity hinges on improved earnings visibility and stabilization above key support. Risks include macroeconomic pressures and absence of current financial metrics, warranting careful monitoring for signs of operational improvement or further deterioration.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
